Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase PHASE2
Enrollment 105
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if an artificial intelligence model will be able to select patients with advanced breast cancer who may respond to a second cyclin-dependent kinase 4/6 (CDK4/6) inhibitor after they have progressed on the first CDK4/6 inhibitor. Patients for this study need to have hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. The main questions the study aims to answer are: If the artificial intelligence model says that a patient's tumor should respond to the second CDK4/6 inhibitor, and that patient receives the second CDK4/6 inhibitor together with fulvestrant (an endocrine therapy also called Faslodex), will it take longer for the tumor to get worse than if the patient receives another type of therapy? Will the tumor respond better? Will the therapy be safe? Researchers will compare the combination of a second CDK4/6 inhibitor plus fulvestrant to the therapy chosen by the physician. Participants will: Take the assigned therapy based on the way the therapy is usually prescribed. Visit the clinic once every month for checkups, tests, and questionnaires. Keep a diary of the pills they take at home.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant. — A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant.
  • Drug: Treatment of physician's choice — Treatment of physician's choice, excluding CDK4/6 inhibitors.

Primary Outcomes

  • Progression free survival (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-31
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 105 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Principal Investigators:
  • Kay Yeung, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of California, San Diego
Contact Information
Study Contact:
Kay Yeung, MD, PhD
858-822-5354
CancerCTO@health.ucsd.edu
Breast Research Team
858-822-5354
cancerCTO@health.ucsd.edu
Kay Yeung, MD, PhD
858-822-5354
CancerCTO@health.ucsd.edu
University of California, San Diego
Interventions
  • Drug: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant. — A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant.
  • Drug: Treatment of physician's choice — Treatment of physician's choice, excluding CDK4/6 inhibitors.
Study Locations (1 sites)
University of California, San Diego, La Jolla, California 92093 United States
Eligibility Criteria
Inclusion Criteria: 1. Age \>18 years 2. Eastern Cooperative Oncology Group performance status 0-2 3. Ability to understand and sign the informed consent document 4. Stated willingness to comply with all study procedures and availability for the duration of the study 5. Advanced breast cancer (defined as unresectable or metastatic) histologically confirmed hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer per American Society of Clinical Oncology/College of American Pathologists (CAP) guidelines. 6. Endocrine-sensitive disease per the 7th International Consensus Conference on Advanced Breast Cancer (ABC7) 2023 guideline: no relapse during the first 2 years of adjuvant endocrine therapy or progression within the first 6 months of first-line endocrine therapy in the metastatic setting. 7. Progression of disease, radiographically per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria or clinically per physician assessment, after a minimum of 6 months of 1 prior line of any CDK4/6 inhibitor therapy plus or minus endocrine therapy in the metastatic setting, or within 6 months of completing adjuvant CDK4/6 inhibitor with endocrine therapy. 8. An additional line of therapy with CDK4/6i is possible and available. 9. Zero to 1 prior line of chemotherapy or antibody-drug conjugates in the metastatic setting. 10. Available next-generation sequencing panel testing results - or possibility to perform next-generation sequencing panel testing - on tumor tissue biopsy collected within 6 months of enrollment but after CDK4/6 inhibitor exposure. Note that If biopsy was performed more than 6 months before enrollment, the patient is not eligible to participate, unless the biopsy is repeated during the prescreening phase. Adequate tissue/testing will be one of these: 1. safe non-osseous tumor site for fresh tissue biopsy and subsequent tissue-based next-generation sequencing testing by any Clinical Laboratory Improvement-certified laboratory. Biopsy and next-generation sequencing testing will be performed as standard of care evaluation. 2. archival non-osseous tumor tissue adequate for standard of care next-generation sequencing testing by any Clinical Laboratory Improvement Amendments-certified labs. 3. prior tissue-based next-generation sequencing testing on tissue that was collected and performed within 6 months of study enrollment. 11. Palbociclib sensitive disease as determined by the palbo-VNN model. 12. Participants can have non-measurable but evaluable disease or measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria 13. Participants must have organ and marrow function as defined below: 1. Leukocytes \> 3,000/microliter 2. Hemoglobin \> 8 g/deciliter 3. Absolute neutrophil count \> 1,200/microliter 4. Platelets \> 75,000/microliter 14. For participants of reproductive potential: 1. Females: use of highly effective contraception for at least 1 month before initiation of treatment with study medications (cycle 1 day 1) and agreement to use such a method during study participation and until 3 months after the end of treatment visit. Only non-hormonal contraception (eg., copper intrauterine device, barrier, condoms with spermicidal, sponge with spermicidal, or diaphragm with spermicidal), is allowed. 2. Males: use of condoms or other methods to ensure effective contraception with a partner during study participation and until 3 months after the end of treatment visit. For partners, use of hormonal contraception is allowed. 15. Palliative radiotherapy is allowed. 16. Participants with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate locoregional central nervous system-specific treatment is not required and is unlikely to be required during the first cycle of therapy. 17. Human immunodeficiency virus-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible. 18. For participants with evidence of chronic hepatitis B virus infection, the viral load must be undetectable on suppressive therapy, if indicated. 19. Participants with a history of hepatitis C virus infection must have been treated and cured. For participants with hepatitis C virus infection who are currently on treatment, they are eligible if they have an undetectable viral load. 20. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible. Exclusion Criteria: 1. Life expectancy less than 6 months. 2. Any medical or psychiatric condition that would prevent the safe use of a CDK4/6 inhibitor or fulvestrant or treatment of physician's choice or the ability to participate in study procedures. 3. Participants who are receiving any other investigational agents within 3 weeks of study enrollment only if there is a known pharmacokinetic interaction with the selected drug. No washout period is otherwise required. 4. Uncontrolled intercurrent illness including ongoing or active infection, congestive heart failure, unstable angina pectoris or cardiac arrhythmia, lung disease requiring continuous oxygen supplementation, decompensated cirrhosis, end-stage kidney disease on dialysis, or psychiatric illness that limits the ability to participate in the study. 5. Unable to have access to abemaciclib, palbociclib, ribociclib, or fulvestrant as a standard of care treatment. 6. Pregnancy or lactation.
Conditions Congenital Diaphragmatic Hernia, Pulmona...
Phase PHASE3
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Tracheal occlusion IDE approved by FDA for congenital diaphragmatic hernia fetuses and standard of care control group

Design

Study type: Interventional Phases: Phase3 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: FETO, Fetal Endoluminal Tracheal Occlusion — Fetal Endoluminal Tracheal Occlusion with Balloon placement for fetuses with congenital diaphragmatic hernia

Primary Outcomes

  • Change lung growth on prenatal imaging (prenatal period up to 40 weeks gestation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-09-30
Completion: 2033-03-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Hospital Medical Center, Cincinnati
Contact Information
Study Contact:
Foong-Yen Lim, MD
(513) 636-6259
Foong-Yen.Lim@cchmc.org
Foong-Yen Lim
513-803-5270
foong.yen.lim@cchmc.org
Cincinnati Children's Hospital Medical Center (CCHMC)
Erin Watters
513-803-7024
erin.watters@cchmc.org
Cincinnati Children's Hospital Medical Center (CCHMC)
Interventions
  • Device: FETO, Fetal Endoluminal Tracheal Occlusion — Fetal Endoluminal Tracheal Occlusion with Balloon placement for fetuses with congenital diaphragmatic hernia
Study Locations (1 sites)
Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, Ohio 45229 United States
Eligibility Criteria
Inclusion Criteria: * Pregnant women 18 years and older, who are able to consent * Singleton pregnancy * Gestational age at enrollment is prior to 296 weeks * Intrathoracic liver herniation * Isolated Left CDH with o/e LHR \< 30% at enrollment (180 to 295 weeks) or * Isolated Right CDH with o/e LHR \< 45% at enrollment (180 to 295 weeks) * Normal fetal karyotype with confirmation by culture results, CMA with non-pathological variants, WES or WGS. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is \> 26 weeks * Cervical length by transvaginal ultrasound \> 20 mm within 24 hours prior to FETO procedure * Patient meets psychosocial criteria * Informed consent understood Exclusion Criteria * Patient \< 18 years of age * Multi-fetal pregnancy * History of natural rubber latex allergy * Preterm labor, cervix shortened (\< 20 mm at enrollment or within 24 hours prior to FETO balloon insertion) or uterine anomaly strongly predisposing to preterm labor, or placenta previa. * Psychosocial ineligibility, precluding consent: * Inability to reside within 30 minutes of Cincinnati Children's Hospital Medical Center and inability to comply with the travel for the follow-up requirements of the trial. * The patient does not have a support person (e.g. spouse, partner, mother) available to stay with the patient for the duration of the pregnancy at Cincinnati Children's Hospital Medical Center. * Bilateral CDH, isolated LCDH with o/e LHR ≥ 30%, isolated RCDH with o/e LHR \> 45%, as determined by ultrasound. * No liver herniation into thoracic cavity * Additional fetal anomaly and chromosomal abnormalities, associated anomalies recognized to alter survival prognosis (i.e., congenital heart disease) or presence of an underlying genetic syndrome (i.e., Fryns) by ultrasound, MRI, or echocardiogram at the fetal treatment center. * Maternal contraindication to fetoscopic surgery or severe maternal medical condition in pregnancy * History of incompetent cervix with or without cerclage * Placental abnormalities (previa, abruption, accreta) known at time of enrollment * Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy * Maternal HIV, Hepatitis-B, Hepatitis-C positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV status is unknown, the patient must be tested and found to have negative results before enrollment. * Positive Hepatitis B surface antigen or presence of Hepatitis C in maternal blood uterine anomaly such as Mullerian duct abnormality, large or multiple fibroids that prohibit safe fetoscopic procedure * There is no safe or technically feasible fetoscopic approach to balloon placement * Participation in another intervention study that influences maternal and fetal morbidity and mortality, or participation in this trial in a previous pregnancy
Conditions Preeclampsia
Phase NA
Enrollment 90
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The MINDBP study will enroll 90 pregnant women at risk for HDP across two sites (MCW and Brown) and randomize them to: (1) mindfulness training (MT) plus wearable biosensors, (2) MT alone, or (3) routine prenatal care. MT participants will receive 8 weekly phone-based MT sessions plus two booster sessions at 1 and 2 months post-intervention. The primary outcome is study feasibility.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Mindfulness training — Mindfulness training with trained instructors
  • Behavioral: Garmin Vivoactive 4 watch — Biofeedback with a wearable biosensor that continuously monitors heart rate variability and generates stress scores.

Primary Outcomes

  • Feasibility of multisite RCT (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-01
Completion: 2028-10-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical College of Wisconsin
Principal Investigators:
  • Anna Palatnik, MD (PRINCIPAL_INVESTIGATOR) - Medical College of Wisconsin
  • Margaret Bublitz, PhD (PRINCIPAL_INVESTIGATOR) - Brown University
Contact Information
Study Contact:
Anna Palatnik, MD
14148056627
apalatnik@mcw.edu
Alyssa Hernandez, DO
4149552781
alyhernandez@mcw.edu
Margaret Bublitz, PhD
401-793-7884
mbublitz@brownhealth.org
Brown University
Interventions
  • Behavioral: Mindfulness training — Mindfulness training with trained instructors
  • Behavioral: Garmin Vivoactive 4 watch — Biofeedback with a wearable biosensor that continuously monitors heart rate variability and generates stress scores.
Study Locations (2 sites)
Brown University, Providence, Rhode Island 02904 United States
Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States
Eligibility Criteria
Inclusion Criteria: * Pregnant patients at gestational age \<= 16 weeks * Live, non-anomalous gestation * Normotensive at enrollment * Meet criteria consistent with 'moderate' to 'high' risk for preeclampsia based on ACOG/USPSTF guidelines for low-dose aspirin administration to prevent hypertensive disorders of pregnancy Exclusion Criteria: * Multiple gestation * Chronic (pregestational hypertension) * Inability of unwillingness to provide informed consent * Active suicidality or psychosis * Ongoing mind-body practice (e.g., yoga, meditation, mindfulness \>= once per week)
Conditions Major Depressive Disorder
Phase PHASE3
Enrollment 550
Locations 60 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: NBI-1065845 — Oral tablet
  • Drug: Placebo — Oral tablet

Primary Outcomes

  • Time from Randomization to Relapse (From randomization to the earliest of relapse or end-of study (up to approximately 32 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-08-18
Completion: 2028-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 550 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Neurocrine Biosciences
Principal Investigators:
  • Clinical Development Lead (STUDY_DIRECTOR) - Neurocrine Biosciences
Contact Information
Study Contact:
Neurocrine Medical Information Call Center
1-877-641-3461
medinfo@neurocrine.com
Interventions
  • Drug: NBI-1065845 — Oral tablet
  • Drug: Placebo — Oral tablet
Study Locations (60 sites)
Neurocrine Clinical Site, Oceanside, California 92056 United States
Neurocrine Clinical Site, Orange, California 92868 United States
Neurocrine Clinical Site, San Jose, California 95124 United States
Neurocrine Clinical Site, New Haven, Connecticut 06520 United States
Neurocrine Clinical Site, Miami Gardens, Florida 33014 United States
Neurocrine Clinical Site, Orlando, Florida 32803 United States
Neurocrine Clinical Site, Palm Bay, Florida 32905 United States
Neurocrine Clinical Site, Tampa, Florida 33629 United States
Neurocrine Clinical Site, Iowa City, Iowa 52242 United States
Neurocrine Clinical Site, Marrero, Louisiana 70072 United States
Eligibility Criteria
Key Inclusion Criteria: * Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder. * Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression. * Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study. * Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score ≥22 at screening and at study baseline (Day 1). * Willing and able to comply with all study procedures and restrictions in the opinion of the investigator. Key Exclusion Criteria: * A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD. * Are considered by the investigator to be at imminent risk of suicide or injury to self or others. * Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode. Note: Other protocol-defined Inclusion and Exclusion criteria may apply.
Conditions Metastatic Breast Cancer
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The research study is to learn how the ACLP can best support patients with stable HR+/HER2- MBC.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Demographics/Lifestyle Survey — Participants will complete all sessions and instruments

Primary Outcomes

  • Safety and Adverse Events (AEs) (Through study completion; an average of 1 year.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-21
Completion: 2029-10-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Principal Investigators:
  • Meroe Morse, MD (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Meroe Morse, MD
713-794-4053
mbmorse@mdanderson.org
Meroe Morse, MD
713-794-4053
mbmorse@mdanderson.org
The University of Texas M. D. Anderson Cancer Center
Meroe Morse, MD
The University of Texas M. D. Anderson Cancer Center
Interventions
  • Other: Demographics/Lifestyle Survey — Participants will complete all sessions and instruments
Study Locations (1 sites)
The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. Patients with HR+/HER2 negative MBC 2. On first- or second-line treatment 3. Life expectancy at least 12 months 4. Only females 5. Age 18 years or older 6. Able to read, write, and speak English 7. Willingness to follow protocol requirements 8. Have a smartphone with access to cellular service or computer access with internet service 9. Oriented to person, place, and time 10. Consume less than 3 servings of fruit and vegetable/day 11. Engage in less than 150 minutes moderate/vigorous intensity activity per week, defined as anything that causes small increases in breathing or heart rate for a sustained amount of time (e.g., brisk walking, bicycling) 12. Engage in a mind-body practice less than 4 times a month Exclusion Criteria: 1. Another primary cancer diagnosis within past 5 years (not including non-melanoma skin cancers) 2. Any major thought disorder (e.g., schizophrenia, dementia) 3. Communication barriers (e.g., hard of hearing) 4. Poorly-controlled or uncontrolled diabetes in the opinion of the physician(s) 5. Extreme mobility issues (e.g., unable to get in and out of a chair unassisted)
Conditions Breast Neoplasms, Carcinoma, Ductal, Bre...
Phase NA
Enrollment 725
Locations 49 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Based on ctDNA test results, participants will either start CDK4/6 inhibitor therapy in addition to hormone therapy or continue hormone therapy with ongoing ctDNA surveillance. This study will compare outcomes to historical controls from the NataLEE trial to determine whether ctDNA-guided timing maintains efficacy while reducing unnecessary treatment. Participants will be followed for up to 9 years with regular blood draws, hormone therapy, imaging as needed, and quality-of-life assessments.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: ctDNA-Guided Treatment Strategy — Circulating tumor DNA testing using Signatera Genome assay is performed every 3 months for up to 4 years to guide timing of CDK4/6 inhibitor initiation. Participants with positive ctDNA results initiate CDK4/6 inhibitor therapy (ribociclib or abemaciclib) plus standard endocrine therapy for a minimum of 2 years. Participants with negative ctDNA results continue endocrine therapy alone with ongoing surveillance. CDK4/6 inhibitor selection and endocrine therapy regimen per the physician's choice following standard-of-care guidelines.

Primary Outcomes

  • Invasive Disease-Free Survival (From the date of surgery up to 9 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-08
Completion: 2037-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 725 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Natera, Inc.
Principal Investigators:
  • Angel Rodriguez, MD (STUDY_DIRECTOR) - Natera, Inc.
Contact Information
Study Contact:
Chelsea Nihill, MS
706-726-6935
signaler@natera.com
Jessica Reyes, BS
844-778-4700
signaler@natera.com
Shakeela Bahadur, MD
Mayo Clinic Arizona
Interventions
  • Device: ctDNA-Guided Treatment Strategy — Circulating tumor DNA testing using Signatera Genome assay is performed every 3 months for up to 4 years to guide timing of CDK4/6 inhibitor initiation. Participants with positive ctDNA results initiate CDK4/6 inhibitor therapy (ribociclib or abemaciclib) plus standard endocrine therapy for a minimum of 2 years. Participants with negative ctDNA results continue endocrine therapy alone with ongoing surveillance. CDK4/6 inhibitor selection and endocrine therapy regimen per the physician's choice following standard-of-care guidelines.
Study Locations (49 sites)
Mayo Clinic Arizona, Phoenix, Arizona 85054 United States
Honor Health Research Institute, Scottsdale, Arizona 85258 United States
University of Arizona Cancer Center, Tucson, Arizona 85719 United States
Marin Cancer Care, Greenbrae, California 94904 United States
Loma Linda University, Loma Linda, California 92354 United States
Cancer and Blood Research Center, Los Alamitos, California 90720 United States
UCLA David Geffen School of Medicine, Santa Monica, California 90404 United States
Stockton Hematology Oncology Medical Group, Stockton, California 95204 United States
Kaiser Permanente NorCal, Vallejo, California 94589 United States
Intermountain Health, Grand Junction, Colorado 81501 United States
Eligibility Criteria
Inclusion Criteria: 1. Signed and dated Informed Consent Form (ICF) obtained prior to any trial-specific screening procedure. 2. Patient is ≥ 18 years-old at the time of ICF signature. 3. Patient is female with known menopausal status at the time of initiation of adjuvant endocrine therapy (ET), or male. 4. Patient with histologically confirmed unilateral and unifocal primary invasive adenocarcinoma of the breast prior to initiating adjuvant chemotherapy, if indicated, or within 6 months of initiating adjuvant endocrine therapy if chemotherapy is not indicated. Patients who receive neoadjuvant endocrine therapy or chemotherapy are allowed to enroll. 5. Patient has breast cancer that is positive for ER and/or PR according to the local laboratory as determined on the most recently analyzed tissue sample. 6. Patient has HER2-negative breast cancer defined as a negative in situ hybridization test (FISH, CISH, or SISH) or an immunohistochemistry (IHC) status of 0 or 1+. If IHC is 2+, a negative in situ hybridization (ISH) test is required to confirm the HER2-negative status. 7. Patient has available archival tumor tissue from the diagnostic biopsy or surgical specimen, for submission to a central laboratory for Signatera testing (unless Signatera Genome clinical testing has already been performed). 8. Patient after surgical resection where tumor was removed completely (i.e., negative microscopic margins on final pathology) and have Anatomic Stage II that is eligible for adjuvant CDK4/6 inhibitors. The criteria to be eligible for adjuvant CDK4/6 inhibitors include N1, or N0 with T3 or T2 with either G3, or G2 with Ki67 greater or equal to 20% or high genomic risk score. Notes: 1. Patients who received neoadjuvant treatment must meet the criteria for stage, grade, Ki67 in any presurgical staging/sample and/or in the surgical specimen. 2. Categorization into the AJCC 8th edition Anatomic Stage Groups requires determination of the T, N and M categories. ALND can be omitted. 9. Patient has no contraindication to adjuvant ET and is planned to be treated with ET for 5 years (since enrollment date) or more. 10. Provider and patient must be agreeable to initiate CDK4/6 inhibitors only upon ctDNA detection. 11. Patient may have received up to 6 months of standard adjuvant ET at the time of enrollment and any amount of neoadjuvant endocrine therapy. 12. Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 13. Patient must not have a clinical contraindication to ribociclib or abemaciclib. 14. Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures. 15. Women of childbearing potential (CBP) must have a confirmed negative serum pregnancy test within 14 days prior to enrollment. 16. Women of reproductive potential should be advised of the potential risk of CDK4/6 inhibitors to a fetus, and use effective contraception during CDK 4/6 inhibitor therapy. Exclusion Criteria: 1. Patient has had prior exposure to a CDK4/6 inhibitor. 2. Patient is concurrently using hormone replacement therapy. 3. Patient with a known contraindication or hypersensitivity to ribociclib or abemaciclib as per the FDA indication label. 4. Patients with a multicentric and/or multifocal and synchronous contralateral breast cancer are ineligible. 5. Patient with distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative surgery. 6. Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 5 years before ICF signature. Note: Patients with prior or concurrent in situ malignancies are eligible provided that adequate curative treatment is completed prior to enrollment. 7. Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, liver cirrhosis or any other significant liver disease, active untreated or uncontrolled fungal, bacterial or viral infections, active infection requiring systemic antibacterial therapy, etc.) or limit life expectancy to ≤5 years. 8. Patient participated in another interventional study and received treatment with an investigational product (or used an investigational device) within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.
Conditions Osteoporosis Secondary, Breast Cancer Fe...
Phase Not Applicable
Enrollment 134
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In women with breast cancer undergoing adjuvant hormone therapy, the marked tissue hypoestrogenism induced by therapy with aromatase inhibitors and/or tamoxifen ± GnRH analogues causes a significant acceleration in bone mass loss, with a consequent increased risk of fracture from the first year of therapy. It is therefore essential to start treatment with antiresorptive drugs and calcium and vitamin D supplementation. It has been hypothesized that vitamin K and α-lactalbumin have an effect in improving the absorption of calcium and vitamin D. In addition, vitamin K promotes gamma-carboxylation of osteocalcin, causing its activation and leading to increased incorporation of hydroxyapatite into the bone, resulting in increased calcium uptake from the blood and other tissues. Studies have reported that a combination of alendronate and vitamin K2 can lead to a decrease in the ratio of uncarboxylated osteocalcin to carboxylated osteocalcin, contributing to an increase in BMD, especially in the femoral neck. α-lactalbumin is able to increase the bioaccessibility of calcium due to its ability to prevent its precipitation at the neutral pH present in the absorptive tracts of the small intestine. Furthermore, α- lactalbumin has a binding site for vitamin D3, and the complexes formed by monomers of this protein and vitamin D have shown good stability in the presence of high vitamin concentrations. Inositol is a carbohydrate structurally similar to glucose which, in its isomeric form D-chiro-inositol, acts on bone remodeling by blocking the activation of osteoclasts through inhibition of the binding of RANK-L to its receptor present on pre-osteoclasts. Our hypothesis is that the use of the combination of vitamin K, α- lactalbumin, and D-chiro-inositol should improve the intestinal absorption of calcium and vitamin D, increasing the percentage of patients able to normalize serum levels of vitamin D and urinary calcium excretion (as a parameter of adequate calcium intake). This aspect, together with the direct effect of these components on bone remodeling, could enhance the anti-resorptive effect of standard therapy with bisphosphonates, improving the quantitative and qualitative parameters of bone. Therefore, we design a prospective randomized pilot study to assess efficacy of the combination of vitamin K, α-lactalbumin, and D-chiro-inositol, comparing patients with standard therapy and patients treated with Synostea®

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Dietary Supplement: Group 1: calcium carbonate/cholecalciferol — Intake of calcium carbonate 500 mg + cholecalciferol 2000 IU
  • Dietary Supplement: Group 2: Synostea® (calcium carbonate/cholecalciferol/vitamin K/α-lactalbumin/ d-chiro-inositol) — Intake of Synostea® : calcium carbonate 400 mg + cholecalciferol 2000 IU + vitamin K (menaquinone 50 μg) + α-lactalbumin (30 mg) + d-chiro-inositol (150 mg)

Primary Outcomes

  • Evaluation of differences in mean vitamin D levels after six months in patients treated with calcium carbonate + cholecalciferoland patients treated with calcium carbonate + cholecalciferol + vitamin K + α-lactalbumin + d-chiro-inositol (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-29
Completion: 2028-03-31
Eligibility
Age: 35 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 134 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Regina Elena Cancer Institute
Principal Investigators:
  • Marialuisa Appetecchia, MD (PRINCIPAL_INVESTIGATOR) - Regina Elena National Cancer Insitute
Contact Information
Study Contact:
Marialuisa Appetecchia, MD
0039 0652666026
marialuisa.appetecchia@ifo.it
Marco Centanni, MD
07736556225
marco.centanni@uniroma1.it
Santa Maria Goretti Hospital
Camilla Virili, MD
camilla.virili@uniroma1.it
Santa Maria Goretti Hospital
Interventions
  • Dietary Supplement: Group 1: calcium carbonate/cholecalciferol — Intake of calcium carbonate 500 mg + cholecalciferol 2000 IU
  • Dietary Supplement: Group 2: Synostea® (calcium carbonate/cholecalciferol/vitamin K/α-lactalbumin/ d-chiro-inositol) — Intake of Synostea® : calcium carbonate 400 mg + cholecalciferol 2000 IU + vitamin K (menaquinone 50 μg) + α-lactalbumin (30 mg) + d-chiro-inositol (150 mg)
Study Locations (2 sites)
Santa Maria Goretti Hospital, Latina, Italy 04100 Italy
Regina Elena National Cancer Institute, Roma, Italy 00144 Italy
Eligibility Criteria
Inclusion Criteria: * caucasian women aged between 35 and 70; * diagnosed with breast cancer undergoing treatment with aromatase inhibitors or tamoxifen + GnRH analogues or aromatase inhibitors + GnRH analogues not started more than 12 months ago, about to start treatment with oral bone resorption inhibitors (alendronate); * vitamin D levels below 30 ng/ml (test carried out no more than 6 months prior to the baseline/T0 visit) * patients able to comply with the procedures and/or requirements of the study * informed consent to participate in the study and data processing, written personally and/or through a witness, before any study-specific procedure is carried out Exclusion Criteria: * uncontrolled diabetes mellitus (HbA1c 8%), severe CRF (eGFR\<30 ml/min); * patients with primary or secondary hyperparathyroidism due to CRF; * baseline vitamin D levels greater than 30 ng/ml; * patients already being treated with anti-resorptive drugs; * patients undergoing steroid therapy; * patients undergoing treatment with other forms of vitamin D (calcifediol, calcitriol) or who require high doses of calcium (hypoparathyroidism); * patients undergoing treatment with drugs that can affect calcium excretion (diuretics); * inability to comply with the procedures required by the study.
Conditions Breast Cancer, Cancer of the Breast
Phase NA
Enrollment 78
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Recent research has shown that, among women with extremely dense breasts and normal results on mammogram, magnetic resonance imaging (MRI) use has significantly reduced the occurrence of breast cancer that is diagnosed during the time between two regular screening mammograms (also known as interval cancers). The investigators have developed and validated an approach to use the whole mammogram image, develop a mammogram risk score (MRS), and calibrate this to the SEER breast cancer incidence rates for US women. This model (Prognosia Breast) generates an absolute 5-year risk of breast cancer and classifies approximately 5.7% of the population as high risk using the ASCO 3% cut point as used for endocrine therapy to reduce risk. Follow-up generates an incidence of 25.2 cases per 1,000 women per year.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Device: Prognosia Breast — The risk output from this algorithm is calibrated to US Surveillance, Epidemiology, and End Results (SEER) 5-year risk and so estimates for each woman the personal 5-year risk.
  • Device: Mammogram — Standard of care annual screening mammogram
  • Device: MRI — MRI at the time of annual screening mammogram

Primary Outcomes

  • Number of successful recommendations for MRI (Feasibility portion only) (Through completion of follow-up (estimated to be 24 months))
  • 2-year detection rate (Randomized Controlled Trial only) (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-09
Completion: 2029-09-30
Eligibility
Age: 25 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 78 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Washington University School of Medicine
Principal Investigators:
  • Tabassum Ahmad, M.D. (PRINCIPAL_INVESTIGATOR) - Washington University School of Medicine
Contact Information
Study Contact:
Tabassum Ahmad, M.D.
314-474-7696
ahmad.tabassum@wustl.edu
Tabassum Ahmad, M.D.
314-474-7696
ahmad.tabassum@wustl.edu
Washington University School of Medicine
Tabassum Ahmad, M.D.
Washington University School of Medicine
Interventions
  • Device: Prognosia Breast — The risk output from this algorithm is calibrated to US Surveillance, Epidemiology, and End Results (SEER) 5-year risk and so estimates for each woman the personal 5-year risk.
  • Device: Mammogram — Standard of care annual screening mammogram
  • Device: MRI — MRI at the time of annual screening mammogram
Study Locations (1 sites)
Washington University School of Medicine, St Louis, Missouri 63110 United States
Eligibility Criteria
Inclusion Criteria: * Normal screening mammogram within 90 days prior to enrollment. Bi-Rads of 1 or 2. * Dense breasts, either: * Class C density ("the breasts are heterogeneously dense, which may obscure small masses") * Class D density ("the breasts are extremely dense, which lowers the sensitivity of mammography") * Assigned female at birth. * Between 40 to 74 years of age (inclusive). * Ability to understand and willingness to sign an IRB approved written informed consent document. Exclusion Criteria: * Screening mammogram with BI-Rads of 0. * Contraindication to MRI with contrast (e.g. claustrophobia, metal objects in the body, known sensitivity/allergy to gadolinium). * Prior or concurrent malignancy whose natural history has the potential to interfere with the study intervention (breast cancer or non-classic LCIS). Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial. * Prior MRI screening of the breast. * Known to be BRCA 1/2 positive or presence of any other known high penetrance genetic marker. * Is receiving any endocrine therapy. * Has breast implants. * Is breastfeeding.
Conditions Early Breast Cancer, Metastatic Breast C...
Phase NA
Enrollment 1050
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This trial is a translational, open-label, monocentric and prospective cohort study of participants with breast cancer aiming to create a combined ESPRESSO (= organelle properties) phenotype and spatial proteomics data collection encompassing four cohorts: * TN eBC = cohort A, * HER2+ eBC = cohort B, * Luminal eBC = cohort C, * dnMBC = cohort D. In total 1050 participants will be enrolled in the study. Laboratory analysis (including ESPRESSO technique) will be conducted on the biological specimen collected during this study. The primary objective is to describe the amount of fatty acids accumulated in lipid droplets, within the four cohorts. As a secondary objective, the analysis will expand to other organelles like lysosomal acidity and nuclear organization. The study is due to last 9 years (4 years of recruitment and 5 years of study participation)

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: Tumor biopsy — As fresh tumor material is required for laboratory analysis purposes (ESPRESSO technique), tumor biopsies will be performed specifically for this study.

Primary Outcomes

  • The amount of fatty acids accumulated in lipid droplets, quantified by the total intensity of a lipid-droplet specific fluorescent dye in the four cohorts (5 years for each participant)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-06
Completion: 2035-02-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1050 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Claudius Regaud
Contact Information
Study Contact:
Florence DALENC, MD, Professor
+33 5311 55 104
Dalenc.Florence@iuct-oncopole.fr
Camille FRANCHET, MD
+33 5 31 15 64 03
Franchet.Camille@iuct-oncopole.fr
Florence DALENC, MD, Professor
+33531155104
Dalenc.Florence@iuct-oncopole.fr
Institut Universitaire du Cancer de Toulouse - Oncopole
Interventions
  • Other: Tumor biopsy — As fresh tumor material is required for laboratory analysis purposes (ESPRESSO technique), tumor biopsies will be performed specifically for this study.
Study Locations (1 sites)
Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, 31059 France
Eligibility Criteria
* Inclusion Criteria: 1. Patient (women or men) with histologically documented breast cancer 2. Early Breast Cancer (eBC) or de novo metastatic BC (dnMBC), regardless the immunohistochemical subtype: Triple Negative BC (ER-negative \[\<10%\], PR-negative \[\<10%\] and HER2-negative \[i.e. null, ultra-low or low\] BC); HER2-positive BC: HER2 overexpression score 3+ or ERBB2 amplification whatever ER/PR expression and proliferation level; Luminal A-like BC: low to moderately proliferative (Ki67\<20%) ER-positive (≥ 10%) PR-positive (≥ 20%) BC and low proliferative (Ki67\< 14%) ER-positive PR-negative (\< 20%) BC; Luminal B-like BC: highly proliferative (Ki67≥ 20%) ER-positive, PR-positive BC or moderately proliferative (14% ≤ Ki67\< 20%) ER-positive PR-negative (\<20%) BC 3. Age ≥ 18 years at the time of study entry 4. Patient followed within a standard of care procedure or clinical trial 5. ECOG performance status ≤ 2 6. Breast cancer treatment not yet started 7. Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol 8. Patient affiliated to a Social Health Insurance in France. * Exclusion Criteria: 1. Known history of positive test for Hepatitis B virus or Hepatitis C virus or Immunodeficiency Virus (HIV) or Hanta virus. 2. Abnormal coagulation contraindicating biopsy 3. Previous or on going treatment for the breast cancer 4. Bone metastases when this is the only site of biopsiable disease for dnMBC patients 5. Any condition contraindicated with blood sampling procedures required by the protocol (including Hemoglobin \< 8g/dl) 6. Patients with known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer 7. Patient pregnant, or breast-feeding 8. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure. 9. Patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship.
Conditions Hypertension
Phase PHASE1
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this study is to compare the change from baseline in systolic blood pressure between KN060 and placebo in patients with essential hypertension over 12 weeks; the secondary objectives are to assess the safety and tolerability of KN060 and to assess the pharmacokinetic and pharmacodynamic properties and immunogenicity of KN060 in patients with essential hypertension. The main questions it aims to answer are: * To verify the efficacy of KN060 in patients with essential hypertension * Safety of KN060 in Subjects Treated for Essential Hypertension Researchers will compare KN060 to placebo (0.9% sodium chloride 100ml) to assess the antihypertensive effect of KN060. Subjects will : * Receive KN060 or placebo by intravenous drip every two weeks for 6 doses. * AOBP, 24hABPM, HBPM,and safety were monitored and recorded.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: KN060 — The dose was calculated based on the fasting body weight of the subject D1, and the corresponding volume of KN060 was drawn and added to 0.9% sodium chloride injection to prepare a 100 ml solution by intravenous drip every two weeks
  • Drug: 0.9% Sodium Chloride Injection — 0.9% sodium chloride 100ml was administered as placebo by intravenous drip every two weeks

Primary Outcomes

  • Mean Systolic Blood Pressure (SBP) Change From Baseline in 24hABPM Adding KN060 or Placebo for 12 Weeks (KN060 or placebo for 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-08-05
Completion: 2027-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Suzhou Alphamab Co., Ltd.
Principal Investigators:
  • Jiguang Wang, Doctor (PRINCIPAL_INVESTIGATOR) - Ruijin Hospital
  • Ningru Zhang, Doctor (PRINCIPAL_INVESTIGATOR) - The First Affiliated Hospital of Bengbu Medical University
  • Caie Wang, Doctor (PRINCIPAL_INVESTIGATOR) - The First Affiliated Hospital of Henan University of Science and Technology
Contact Information
Study Contact:
Yanrong Dong, Master
+86 18914005458
yanrongdong@alphamab.com
Jiguang Wang, Doctor
+86 13725517405
jiguangw@163.com
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Interventions
  • Drug: KN060 — The dose was calculated based on the fasting body weight of the subject D1, and the corresponding volume of KN060 was drawn and added to 0.9% sodium chloride injection to prepare a 100 ml solution by intravenous drip every two weeks
  • Drug: 0.9% Sodium Chloride Injection — 0.9% sodium chloride 100ml was administered as placebo by intravenous drip every two weeks
Study Locations (1 sites)
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality China
Eligibility Criteria
Inclusion Criteria: 1. men or women ≥ 18 years of age and ≤ 65 years of age; 2. patients with essential hypertension who are not receiving drug therapy or are receiving stable monotherapy (stable therapy: no change in antihypertensive drugs and doses within 30 days before screening); 3. AOBP mean sitting SBP ≥ 140 and \< 180 mmHg (at least 5 minutes rest before measurement, 3 measurements averaged over at least 1 minute apart) and mean SBP ≥ 130 and ≤ 160 mmHg at 24 hours ABPM; Exclusion Criteria: 1. secondary hypertension: kidney disease, endocrine disease, cardiovascular disease and moderate to severe obstructive sleep apnea without CPAP treatment; 2. Grade 3 hypertension (severe): mean AOBP sitting SBP ≥ 180 mmHg, and/or DBP ≥ 110 mmHg; mean ABPM SBP \> 160 mmHg, and/or mean DBP ≥ 100 mmHg; 3. Patients with a history of hypertensive emergencies, or hypertensive sub-emergencies who have severe hypertension with headache, chest tightness, irritability, and epistaxis; 4. high risk of bleeding or abnormal relevant indicators; 5. long-term use of anticoagulants or antiplatelet drugs, including aspirin at any dose, due to treatment; 6. currently using, or within 30 days before dosing or expected to use any drug or other component known to affect blood pressure during the study; 7. Type 2 diabetes with substandard blood glucose control: fasting blood glucose \> 7.8 mmol/L, or 2-hour postprandial blood glucose/random blood glucose \> 10.0 mmol/L, or HbA1c \> 7%; 8. any cardiovascular event within 6 months prior to screening 9. unstable heart disease, such as uncontrolled symptomatic arrhythmia, atrial fibrillation, heart failure NYHA ≥ III, severe left ventricular hypertrophy, or a history of valvular heart disease; 10. 12-lead ECG showed significant abnormal heart rate, arrhythmia or myocardial ischemia; 11. echocardiography revealed heart failure:LVEF\< 50%; abnormal ventricular diastolic function
Conditions Primary Open Angle Glaucoma (POAG)
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to to evaluate how well Direct Selective Laser Trabeculoplasty (DSLT) lowers eye pressure in eyes of adult, non-Caucasian participants with primary open angle glaucoma. The main question it aims to answer is: What is the washed out eye pressure (eye pressure when not on any glaucoma medications) of participants 6 months after the Direct Selective Laser Trabeculoplasty (DSLT) procedure compared to the washed out eye pressure of participants prior to the DSLT procedure. Participants will: Undergo the DSLT procedure in one or both eyes and visit the clinic 1 month, 3 months, and 6 months after the procedure to have their vision and eye pressure measured.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Direct Selective Laser Trabeculoplasty — DSLT using the Belkin Vision Eagle Device

Primary Outcomes

  • IOP reduction at 6 months washed out post-DSLT compared with washed out baseline IOP. (6 Months post-DSLT)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-16
Completion: 2026-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Select Eye Care
Contact Information
Study Contact:
Scott E LaBorwit, MD
410-821-6400
scott.laborwit@vipeyes.com
Research Coordinator
410-821-6400
hshea@vipeyes.com
Select Eye Care
Interventions
  • Device: Direct Selective Laser Trabeculoplasty — DSLT using the Belkin Vision Eagle Device
Study Locations (1 sites)
Select Eye Care, Elkridge, Maryland 21075 United States
Eligibility Criteria
Inclusion Criteria: * Adult patients of Black African descent scheduled to undergo DSLT treatment in one or both eyes. * Diagnosis of mild to moderate primary open angle glaucoma (POAG). * Mild to moderate POAG will be defined as Stage 2 or better of the Hodapp-Anderson-Parrish glaucoma staging system. * Treatment naive or washed out IOP at time 0 ranging from ≥ 21 through 32 mm Hg. Exclusion Criteria: * Screened patients who were on IOP-lowering medications who did not successfully complete medication washout at the time of the procedure (time 0). * Previous glaucoma surgeries/interventions: * Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt). * Secondary glaucoma: * Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases. * Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator. * Subjects who are pregnant, breast-feeding, or intend to become pregnant during the study period as determined by verbal inquiry.
Conditions Thrombocytopenia
Phase PHASE2
Enrollment 56
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-arm study planned to enroll 56 breast cancer patients who experienced grade 2 or higher thrombocytopenia following prior chemotherapy and achieved normalization (platelet count ≥100 × 109/L and ≥200 × 109/L) through intervention.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Herombopag Olamine Tablets — Herombopag 7.5 mg po qd,d1-14

Primary Outcomes

  • Proportion of grade I thrombocytopenia according to CTCAE4.0 (From enrollment to the end of treatment at 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-10-13
Completion: 2027-09-26
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 56 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Principal Investigators:
  • Yinduo Zeng, MD (PRINCIPAL_INVESTIGATOR) - Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Information
Study Contact:
Tao Qin, MD
86-02034071337
qintao5471@163.com
Tao Qin, MD
86-02034071337
qintao5471@163.com
Sun Yat-sen Memorial Hospital
Interventions
  • Drug: Herombopag Olamine Tablets — Herombopag 7.5 mg po qd,d1-14
Study Locations (1 sites)
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong 510120 China
Eligibility Criteria
Inclusion: * Age 18-75 years, any gender; * Pathologically diagnosed with breast cancer based on histological or cytological examination, and previously treated with neoadjuvant anti-HER-2 therapy followed by T-DM1 adjuvant therapy; * Experienced grade 2 or higher tumor treatment-related thrombocytopenia during the previous T-DM1 treatment cycle, with platelet count restored to ≥100 × 109/L and ≤200 × 109/L prior to the next treatment; * ECOG performance status score: 0-2; * Planned to undergo at least two additional treatment cycles including T-DM1 administration, with the dose of T-DM1 in the current cycle consistent with the previous cycle; * Expected survival of ≥12 weeks and able to tolerate the current treatment regimen for at least two cycles or more; * Expected to have good compliance, able to follow up on treatment efficacy and adverse reactions as required by the protocol. Exclusion: * A history of other malignant tumors diagnosed within the past 3 years; * Patients with mental or neurological disorders who are unable to cooperate; * Patients who are scheduled to undergo or have previously undergone organ or bone marrow transplantation; * Patients with hematopoietic system disorders other than chemotherapy-induced thrombocytopenia (CTIT), including but not limited to leukemia, primary immune thrombocytopenia, myeloproliferative disorders, multiple myeloma, and myelodysplastic syndrome; * Patients with a history of any arterial or venous thrombotic events within the past 6 months prior to screening; * Severe bleeding manifestations within 2 weeks prior to screening, such as gastrointestinal or central nervous system bleeding; * Participation in a clinical trial of the same type of drug within 4 weeks prior to enrollment; * Pregnant or lactating women; * Patients with a history of hypersensitivity to the study drug; * Patients deemed ineligible by the investigator.